**Sir,**

We appreciate the attention given by Drs Dutt, Salvesen, Greulich, Sellers, Beroukhim and Meyerson to our recent publication 'The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas\' ([Shoji *et al*, 2009](#bib8){ref-type="other"}). In this article, we report a 2% mutational frequency of *AKT1* (E17K) among 101 endometrial carcinomas. We also described that these two *AKT1* mutant tumours do not possess any mutations in *PIK3CA*, *PTEN* and *K-Ras*. Our report has proposed two issues to be clarified: (1) Are there any 'oncogenic\' mutations in other AKT family members in endometrial carcinomas? (2) Are all the AKT family mutations mutually exclusive with other PI3 kinase-AKT-activating mutations?

Including the data in their earlier report, [Dutt *et al* (2008](#bib3){ref-type="other"}) revealed mutations in *AKT2* and *AKT3*, as well as in *AKT1*. As for *AKT1* (E17K) mutations, their data and our data are compatible, showing that *AKT1* mutations were detected in 2% of the endometrioid subtype in endometrial cancer. Compared with the accumulative data in *AKT1* (E17K) mutations, mutations in *AKT2* and *AKT3* are not well characterised. [Carpten *et al* (2007)](#bib1){ref-type="other"} and [Kim *et al* (2008)](#bib4){ref-type="other"} reported no E17K mutations in *AKT2* and *AKT3* in breast, colorectal, gastric, hepatocellular, lung carcinomas and acute leukaemias. [Davies *et al* (2008](#bib2){ref-type="other"}) first reported *AKT3* (E17K) mutations in melanoma at 1.5% frequency. [Parsons *et al* (2005)](#bib7){ref-type="other"} found two mutations of *AKT2* (S302G and R371H) in 204 colorectal cancer samples, and [Soung *et al* (2006)](#bib9){ref-type="other"} reported one missense mutation (A377V) and two possible splice-site mutations in intron 11 of *AKT2* in gastric and lung adenocarcinoma. However, the physiological role of *AKT2* mutations, including those (D399N, R368C and D32H) reported by [Dutt *et al* (2008](#bib3){ref-type="other"}), has not been validated yet. In addition, the *AKT3* (E438D) mutation has not been reported in any type of tumours. It is important to clarify whether these rare AKT2/3 mutations cause an oncogenic effect in cancer.

We previously reported that *PIK3CA* mutations frequently coexist with mutations in *PTEN* and/or *KRAS*, and suggested that the *PIK3CA* mutation might require another upstream input to fully activate the PI3K kinase--AKT pathway ([Oda *et al*, 2005](#bib5){ref-type="other"}, [2008](#bib6){ref-type="other"}). Their data of coexistent mutations in *AKT1* (E17K) and *KRAS* (G13D) suggest that the *KRAS* mutation alone is insufficient for a full activation of the PI3 kinase--AKT pathway. Their data are not inconsistent with the hypothesis that the *AKT1* (E17K) mutation and the *PIK3CA* mutation are mutually exclusive. The coexistent mutations of *AKT3* and *PIK3CA* in one sample suggest that some types of *AKT* mutations (non-E17K) might coexist with *PIK3CA* mutations to enhance the activation of the PI3 kinase--AKT pathway. Further analyses are necessary to clarify the frequency of coexistent mutations in *AKT1* (E17K), *AKT2/3* and other mutations.

Their current data and our data suggest that the PI3 kinase--AKT pathway is prevalently activated in endometrial cancer through various genetic alterations and their combinations. Further analyses in *AKT*, *PIK3CA* and other PI3 kinase-AKT-related genes would be helpful to comprehensively understand the mechanism of activation in this pathway and to use PI3K-targeted therapies in various types of cancer.

We thank Dr Dutt and colleagues for their recognition of our work.
